(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the formation of the Scientific and Strategic Advisory Board (“SSAB”) with a renowned group of physicians and scientists. Members of the SSAB include Dr. Daniel Von Hoff, Dr. Kazimierz Roszkowski-Sliz and Dr. Robert Gillies.
22 March 2018